RxDoctor Payments Data

Alberto Rojas, MD

Psychiatry · Miami, FLNPI 1104357839

Payments from drug & device makers

$12,953in general payments, 2019–2025

Across 123 payments — averaging $105.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$968
  • Otsuka America Pharmaceutical, Inc.$683
  • Teva Pharmaceuticals USA, Inc.$654
  • Alkermes, Inc.$391
  • plus $868 from 10 others

What the payments were for

  • Food & beverage$5,36498%
  • Education$882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,953 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$331,165
Medicare patients
654
Services billed
2,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$17,230
Mirtazapine798$12,394
Aripiprazole108$11,892
TrintellixVortioxetine Hydrobromide19$8,934
Sertraline Hcl1,125$5,705
Quetiapine Fumarate506$4,856
Escitalopram Oxalate654$3,136
Temazepam166$2,136
Trazodone Hcl579$2,065
Alprazolam457$1,871
Memantine Hcl115$1,531
Clonazepam298$1,381
Olanzapine70$1,375
Duloxetine Hcl62$1,024
Venlafaxine Hcl ErVenlafaxine Hcl65$863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$683$17,23014 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$8,93419 claims
Almatica Pharma LLCSertraline Hcl$209$5,7051,125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →